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Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the 
treatment of diabetes and their clinical relevance  
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Abstract 
Introduction: A more concentrated insulin glargine formulation, containing 300 U/mL (Gla-
300) was approved in 2015 in the US and Europe for the treatment of diabetes mellitus in 
adults.  
Areas covered: This review focuses on the pharmacokinetics (PK) and pharmacodynamics 
(PD) of Gla-300 from studies published up to May 2016. The clinical relevance of this new 
formulation will be addressed. 
Expert opinion: Gla-300 was developed to produce a more flat and more prolonged PK/PD 
profile compared with insulin glargine 100 U/mL (Gla-100) in order to maintain effective 
glycaemic control and reduce the risk of hypoglycaemia. Compared to Gla-100, Gla-300 
achieves lower and delayed peak concentrations with a PK exposure that is more stable and 
evenly distributed across a 24-h dosing interval. As a consequence, Gla-300 results in a 
consistent glucose-lowering effect with less variability over a 24-h dosing interval, which 
translates to a reduction in the rate of hypoglycaemia (particularly nocturnal events).  
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1. Introduction 
Diabetes mellitus is a chronic condition currently estimated to affect 415 million people 
worldwide, and prevalence is expected to increase to 642 million people by 2040 [1]. 
Approximately 90%–95% of diagnosed cases are type 2 diabetes mellitus (T2DM) with type 
1 diabetes (T1DM) comprising the remaining 5-10%. As T1DM tends to occur at a much 
younger age, those affected have a higher prevalence of complications than T2DM patients of 
a similar age [2].  
2. Overview of current insulin therapy 
Insulin remains the most effective means of consistent blood glucose control in diabetes, 
albeit limited by hypoglycaemia, weight gain and the need for parenteral administration. 
Subcutaneous injection of different formulations aims to replicate the endogenous pattern of 
insulin secretion observed in non-diabetic subjects as closely as possible without 
hypoglycaemia. Depending on their pharmacological profile following subcutaneous 
administration, the duration of action of insulin preparations can be classified as short-acting 
(prandial insulins), intermediate-acting, long-acting and longer-acting (basal insulins), or as 
premixed formulations. 
Basal insulins are a fundamental component of insulin therapy for both T1DM and T2DM. 
Since 1946, Neutral Protamine Hagedorn (NPH) is the predominant basal insulin in clinical 
use globally. However, variability in absorption from the subcutaneous tissue, due to the need 
for re-suspension, as well as the time-action profile (peak activity 4-6 hours [h]) confers an 
increased propensity for between-meal and nocturnal hypoglycaemia [3,4]. In the 1980s, 
recombinant DNA technology enabled modifications to the insulin molecule resulting in 
soluble long-acting insulin analogues that did not require re-suspension before 
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administration; these showed improved pharmacokinetic (PK)/pharmacodynamic (PD) 
profiles compared with NPH [4]. Insulin glargine 100 U/mL (Gla-100, Lantus
®
; Sanofi, Paris, 
France) was the first approved in 2000, followed by insulin detemir (Levemir
®
; Novo 
Nordisk, Bagsværd, Denmark) in 2005. Both show a lower incidence of nocturnal 
hypoglycaemia compared with NPH due to improved time-action profiles and reduced day-
to-day glucose variability. Glargine is administered once daily and detemir once or twice-
daily. More recently, two longer-acting insulin formulations have been introduced, insulin 
degludec (Tresiba
®
, Novo Nordisk) in 2014 and insulin glargine 300 U/mL (Gla-300, 
Toujeo
®
, sanofi) in 2015. Development of a third longer-acting insulin, PEGylated lispro was 
recently discontinued due to safety concerns relating to elevated liver-function tests, changes 
in the lipid-profile, and increased liver fat [5,6]. 
3. Introduction to Gla-300 
The development of new longer-acting insulin analogues has allowed for reduction in the 
peak-to-trough ratio coupled with a more prolonged and more consistent insulin coverage 
beyond 24 h, thus enabling glycaemic targets to be achieved with reduced risk of 
hypoglycaemia [7]. Extending the duration of insulin effect also improves flexibility around 
the time of dosing, simplifies insulin dose titration and allows a greater proportion of patients 
to reach their glycaemic targets [8]. This article reviews the pharmacological characteristics, 
and efficacy and tolerability of subcutaneous once-daily Gla-300 as basal insulin therapy in 
patients with T1DM or T2DM.  
4. Chemistry 
The active substance of Glar-300 is insulin glargine, which differs from human insulin in two 
ways: elongation of the C-terminal of the β-chain, due to the retention of two di-arginyl 
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molecules at position B30, and substitution of asparagine with glycine at position A21 (Box 
1). These changes alter the isoelectric point of the molecule and improve its stability [9]. 
Insulin glargine binds specifically to the human insulin receptor with the same 
pharmacological effects as human insulin [10]. Gla-300 has the same molecular structure, 
metabolism and mode of protraction (forming subcutaneous precipitates) as Gla-100 (see PK 
of Gla-300).  
5. Clinical Pharmacology of Gla-300 
The clinical pharmacology data on Gla-300 is based on 6 randomised, Phase I studies (Table 
1), comprising one single-dose study in healthy subjects [10], and 2 single-dose studies [11] 
and 3 multiple-dose studies [12-14] in subjects with T1DM. With the exception of one study 
that used continuous glucose monitoring (CGM) [14], all studies used the euglycaemic clamp 
technology over a period of 24 to 36 h after the last dose. In addition, a single phase II study 
in patients with T1DM provides information on within- and between-day variability in the 
glucose-lowering effect of Gla-300 [15].  
6. Pharmacokinetics and metabolism of Gla-300 
As the PK of Gla-100 is well described [16,17], PK assessment of Gla-300 was based on a 
comparison of Gla-300 with Gla-100.  
6.1. Absorption 
Insulin glargine is soluble at acidic pH (~4.5) and precipitates after subcutaneous injection 
into the neutral pH of the interstitial fluid, resulting in delayed absorption and a prolonged 
duration of action [17,18]. The pH-dependent precipitation and re-dissolution of insulin 
glargine is dependent upon the concentration of the injected solution [11,19]. This glargine-
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specific phenomenon may result in a surface-dependent release, proportional to the volume 
(surface area) of the amorphous precipitate [11].  
Compared with Gla-100, the subcutaneous injection volume for the same number of insulin 
units is reduced by two-thirds with Gla-300 thereby creating a more compact subcutaneous 
depot with a surface area that is about half that of Gla-100 (Figure 1). As a result, there is 
reduction in the dissolution rate of the subcutaneous precipitate, leading to an increased 
residence time in the subcutaneous tissue, and longer exposure to enzymatic inactivation by 
tissue peptidases [20-22]. This more gradual and prolonged release of Gla-300 leads to 
prolongation of action compared with Gla-100 [11-13]. A similar increase in residence time 
in the subcutaneous tissue and consequent reduction in bioavailability has been observed with 
other insulins (e.g. NPH and ultralente) that also rely on precipitation in the subcutaneous 
space to prolong their time action profile [23]. Due to the increased subcutaneous retention 
time and a lower bioavailability compared with equivalent doses of Gla-100 [10], a higher 
dose of Gla-300 may be required to achieve a similar glycaemic response.  
Two single-centre, randomised, double-blind crossover studies evaluated single subcutaneous 
doses of Gla-300 compared with Gla-100, 0.4 U/kg in Japanese or European subjects with 
T1DM (see Table 2 for doses). Both studies adopted the euglycaemic clamp procedure 
although using different glycaemic control devices (STG-22
®
 and Biostator
®
, respectively) 
with a 5-20 day washout period between each of the treatment periods [11]. In European 
subjects, single doses of Gla-300 (0.4, 0.6 and 0.9 U/kg) resulted in a serum insulin glargine 
concentration (INS) profile that was flatter and more prolonged compared with Gla-100 (0.4 
U/kg) during a 36 h clamp period [11] (Figure 2). Maximum serum concentration (Cmax) was 
later than with Gla-100 (12-16 h versus 8-12 h), with reduced overall exposure (area under 
the INS time curve from time 0 to 36 h [INS-AUC0–36h]) (Table 2). The median time to 50% 
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of insulin glargine exposure over the whole 36 h clamp period (T50%-INS-AUC0-36) was also 
longer for Gla-300 than Gla-100 (15-19 h versus 13-14 h), indicating a more prolonged and 
more evenly distributed exposure profile. Results were generally similar in Japanese subjects 
(Figure 2, Table 2).  
Multiple doses of Gla-300 at two dose levels (0.4 and 0.6 U/kg) and Gla-100 at 0.4 U/kg 
were administered to two cohorts of European patients (n=30) with T1DM over an 8-day 
period [12]. At steady state, the insulin concentration profile the 0.4 U/kg dose was more 
constant and more evenly distributed especially over the first 24 h of the 36 h clamp with 
Gla-300 compared with Gla-100 (Figure 3) [12]. Exposure of Gla-300 at 24-h (INS-AUC0–
24h) was 17% lower than with Gla-100. The prolonged exposure with Gla-300 was supported 
by the time to 50% of insulin exposure (T50%-INS-AUC0–36h) being ~3 h longer for Gla-300 
than Gla-100 during the full 36-h clamp period (~14 versus ~11 h) (Table 3). Gla-300 also 
showed less fluctuation in insulin exposure compared with Gla-100, as shown by a smaller 
perturbation (swing) in the concentration profile of <1 versus 1.8 for Gla-100.  
6.2. Distribution 
The estimated terminal median half-life of Gla-300 0.4 U/kg in subjects with T1DM is longer 
than that of Glar-100 (19 h versus 13.5 h) [12], as it is determined by the rate of absorption 
from the subcutaneous tissue and is independent of dose [24]. Based on this half-life, insulin 
glargine blood concentrations with Gla-300 are estimated to achieve steady state after 3 to 4 
days, compared with 2 to 3 days with Gla-100 [25]. The longer half-life of Gla-300 results in 
longer availability of Gla-300, with levels still measurable in excess of 30 h after dosing 
(Figure 3).  
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6.3. Pharmacokinetic Variability 
Within-day fluctuation and between-day reproducibility in insulin concentrations with Gla-
300 at steady-state was investigated in a double-blind, randomised, two-treatment, two-
period, crossover euglycaemic clamp study in subjects with T1DM (n=50) who were treated 
with 0.4 U/kg of Gla-300 as a standard cartridge formulation or a formulation with enhanced 
stability through the addition of polysorbate-20 [13]. A 24-h euglycaemic glucose clamp was 
carried out on the sixth day of treatment, after steady state had been achieved. There was low 
variability in insulin concentrations, with median cumulative exposure increasing linearly 
over the 24 h clamp period with an even distribution over each 12-h time period (Figure 4). 
The median bi-directional fluctuation in exposure around the average concentration over 24 h 
(11.3 μU/mL) was 3.3 μU/mL. Diurnal fluctuation in exposure (within-day variability) was 
low; the median peak-to-trough ratio of insulin concentration profiles was 1.8, with both the 
swing and peak-to-trough fluctuation being <1. Day-to-day reproducibility of exposure was 
high; the between-day within-subject coefficients of variation for total systemic exposure 
(INS-AUC0–24h) and maximum insulin concentration (INS-Cmax) were 17.4% and 33.4%, 
respectively. In summary, this study confirmed that Gla-300 provides predictable, evenly 
distributed 24-h coverage with low diurnal fluctuation in insulin concentrations and a high 
level of between-day reproducibility in insulin glargine exposure [13].  
6.4. Metabolism of Gla-300 
Insulin glargine mimics the physiology of human insulin. Similar to maturation of human 
insulin in β-cells, after subcutaneous injection, insulin glargine undergoes rapid 
transformation in the subcutaneous tissue to form 2 active metabolites with in vitro activity 
similar to that of human insulin, M1 (Gly
A21
) and M2 (Gly
A21
, des-Thr
B30
) [26]. The M1 
metabolite accounts for approximately 90% of the daily plasma insulin available [27,28]. 
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Both metabolites have a very low affinity for the human insulin-like growth factor-1 receptor 
(IGF-1R) and lower mitogenic properties compared with the parent compound and similar to 
or lower than human insulin [29].  
In patients with T1DM, the metabolites of Gla-300 and Gla-100 were quantified using liquid 
chromatography tandem mass spectrometry [25]. Gla-300 showed the same metabolism as 
Gla-100, with the M1 metabolite being the principal active moiety circulating in blood. 
Steady-state concentrations of M1 were dose dependent and achieved after 2 days for Gla-
100 and 3-4 days for Gla-300, and were quantifiable up to 32 h and 36 h (clamp end), 
respectively (Figure 5A). M1 values for Gla-300 also showed a longer duration of action and 
a flatter PK profile compared with M1 profiles after Gla-100 (Figure 5B). 
7. Pharmacodynamic Characteristics of Gla-300  
The euglycaemic glucose-clamp technique is regarded as the gold standard for investigating 
PD profiles of insulin preparations [30]. Studies are usually conducted in patients with T1DM 
as they have no endogenous insulin secretion. The amount of glucose infused over time, 
expressed as glucose infusion rate (GIR), necessary to maintain blood glucose at the target 
blood glucose level, accurately reflects the PD effect of the insulin preparation [31].  
7.1. Pharmacodynamic - Glucodynamic Profile of Gla-300  
Following single subcutaneous doses of Gla-300 in European (0.4, 0.6 and 0.9 U/kg; n=24) 
and Japanese (0.4 and 0.6 U/kg; n=18) subjects with T1DM, the GIR profile was flatter and 
more prolonged than with Gla-100 (0.4 U/kg) during the 36 h clamp period [11] (Figure 2). 
The total insulin activity (area under the body-weight standardised GIR time curve from time 
0 to 36 h [GIR-AUC0–36h]) increased in a dose-dependent manner with Gla-300 (Table 2). 
The time to 50% of insulin activity (GIR-AUC0–36h) was approximately 5 h longer for all Gla-
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300 doses than for Gla-100 (~18 h versus ~13 h),especially for the 0.6 and 0.9 U/kg doses. In 
both studies, glucose utilisation was delayed, with maximum effect lower for Gla-300 at 0.4 
and 0.6 U/kg compared with Gla-100 at 0.4 U/kg. Glucose-lowering activity was detected for 
up to 36 h with all doses of Gla-300.  
In another study, multiple doses of Gla-300 0.4 and 0.6 U/kg and Gla-100 0.4 U/kg were 
administered over an 8 day period to two cohorts of European patients (n=30) with T1DM 
[12]. After dosing at 0.4 U/kg, the steady state GIR profile was more constant and more 
evenly distributed and remained at a higher level after 24 h with Gla-300 compared with Gla-
100 (Figure 3) [12]. The maximum level of glucose utilisation (GIRmax) was significantly 
lower by 20% with Gla-300 at a dose of 0.4 U/kg (Table 3). The time to 50% of insulin 
activity (GIR-AUC0–36h) was also longer for Gla-300 for both the 0.4 and 0.6 U/kg dose 
levels (~14 h) than for Gla-100 at 0.4 U/kg (11-12 h) during the 36-h clamp period. After the 
final dose on day 8, blood glucose was maintained at ≤105 mg/dL for longer with Gla-300 
than Gla-100 at 0.4 U/kg (33 h versus 29 h). Similarly, during the 36-hour clamp period, 
blood glucose was more tightly controlled and was maintained at or below 110, 130 and 150 
mg/dL, as well as the level of euglycaemia (≤105 mg/dL), for longer with both doses of Gla-
300 than with 0.4 U/kg Gla-100. Following Gla-300 0.6 U/kg, blood glucose remained at or 
below 105 mg/dL for a median time of 35 h.  
7.2. Variability in Glucose-Lowering Effect 
Ideally, a long-acting insulin preparation should exhibit low diurnal variability (fluctuation) 
and low day-to-day variability (high reproducibility) to facilitate accurate dosing schedules. 
Day-to-day within subject variability in the glucose-lowering effect of Gla-300 at steady-state 
was investigated in a double-blind, randomised, two-treatment, two-period, crossover study 
in subjects with T1DM (n=50) who were dosed with 0.4 U/kg of Gla-300 [13]. A 24-h 
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euglycaemic clamp on day 6 showed that the cumulative glucose lowering effect of Gla-300 
was linear over this period and essentially equivalent for the two 12 h periods reflecting the 
cumulative exposure of Gla-300 (see Figure 4). The evenly distributed glucose-lowering 
effect of Gla-300 was confirmed by the AUC for GIR (AUCGIR) across one 24-h dosing 
interval, with similar glucose-lowering effect over each of the four 6-h intervals. The median 
fluctuation in GIR (within-day PD variability) was 1.0 (interquartile range 0.8–1.1) 
mg/kg/min, and the within and between-subject coefficient of variation in GIR-AUC0-24 was 
35% and 43%, respectively.  
24-h glucose variability was assessed using CGM in a single-centre, 2-sequence, 2-period, 
open label cross-over study comparing Gla-100 and Gla-300 in 20 Japanese people with 
T1DM, [14]. CGM was performed over 3 days at the end of screening and each of the 
treatment periods over a 4 week period. Glucose variability over 24 h was measured as the 
absolute AUC above and below the individual average plasma glucose value on the second 
day of CGM. The 24 h glucose variability was not statistically different between Gla-300 and 
Gla-100 (treatment ratio 0.96; 90 % CI 0.79–1.16), with similar variability during day 
(treatment ratio 1.01; 90% CI 0.84-1.21) and night (treatment ratio 0.94; 90%, CI 0.69-1.27) 
[14].  
Variability was further investigated in a multicentre, 16-week, open-label, randomised, 
parallel group, phase II study in patients with T1DM (n=59) who received either Gla-300 or 
Gla-100 once daily in combination with rapid-acting mealtime insulin, with crossover 
between morning and evening injections [15]. Each treatment period was 8 weeks, with 
insulin dose titration over the first 6 weeks and fixed doses for the final 2 weeks during which 
the CGM data were evaluated. Gla-300 injected either in the morning or the evening showed 
lower within- and between-day glucose variability and a similar percentage time in the sensor 
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target glucose range (4.4-7.8 mmol/L, primary outcome) compared with Gla-100 [15] 
(Figure 6). When morning and evening injection periods were combined, within-subject 
blood glucose variability parameters were consistently lower with Gla-300: total standard 
deviation lower by 7.4%, within-day variability by 5.4%, variability between daily means by 
14.3% and variability between days for the same time of day by 7.2% (all non-significant). 
The reduced within-subject variability with Gla-300, irrespective of morning or evening 
administration, indicates that some flexibility in injection times is possible. 
8. Pharmacokinetic and Pharmacodynamic Characteristics of Gla-300 in Special 
Patient Populations 
8.1. Children and Adolescents 
As the PK and PD profile of Gla-300 in children and adolescents (<18 years) has not been 
studied the use of Gla-300 is not recommended in this patient population [24,32]. A dedicated 
randomised controlled trial comparing Gla-300 and Gla-100 in children and adolescents aged 
6-17 years with T1DM (EDITION JUNIOR) has commenced enrolment [33]. 
8.2. Elderly patients 
While post-hoc analyses from phase III trials do not indicate differences in safety and 
efficacy profile among patients ≥65 years [34], caution is recommended when Gla-300 is 
administered to elderly patient’s ≥65 years. A dedicated randomised controlled trial 
comparing Gla-300 and Gla-100 in elderly patients with T2DM (EDITION SENIOR) has 
completed enrolment [35]. 
13 
 
8.3. Renal or Hepatic Impairment 
Due to progressive deterioration of renal function, insulin requirements may be reduced in 
elderly patients (aged ≥65 years) [24]. In addition, insulin requirements may a need to be 
reduced in younger patients with renal impairment (because of reduced insulin elimination) 
or hepatic impairment (because of reduced insulin metabolism and reduced capacity for 
gluconeogenesis) [24]. As there is a lack of data concerning the effects of renal or hepatic 
impairment on the PK of Gla-300, patients with renal or hepatic impairment receiving Gla-
300 may require more frequent glucose monitoring and dose adjustment [32].  
9. Clinical efficacy 
9.1. Phase II studies 
As described in section 7.2, a single phase II trial in adults with T1DM (n=59) [15] showed 
that the proportion of time spent within a glucose range of 4.4–7.8 mmol/L in the last 2 
weeks of each treatment period (primary endpoint) did not differ significantly with Gla-300 
or Gla-100 [least squares mean difference 0.75 %; 95 % CI –3.61 to 5.12]. However, pooled 
average glucose profiles showed that Gla-300 provided more stable glucose levels throughout 
the day than Gla-100 for both morning and evening injections, with less glucose excursion, 
and lower between-day glucose variability (Figure 6).  
9.2. Phase III studies 
The EDITION trial programme, comprising 6 randomised, controlled, open-label, 
multicentre, treat-to-target, 6-month Phase IIIa trials compared the efficacy and safety of Gla-
300 with Gla-100 (Table 5) [20,21,36-39]. Each trial was extended by 6 months to 
investigate long-term safety [40-45]. Two trials in patients with T2DM (EDITION 1 and 2) 
evaluated flexible dosing intervals during the 6-month extension period in a subgroup of 
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patients, with patients asked to take their evening doses of Gla-300 3 h earlier or later than 
their chosen injection time on at least 2 days per week, or continue with their fixed 24-h 
dosing intervals [46]. The trials used the same weekly dose titration to achieve the target 
fasting plasma glucose (FPG) concentration of 4.4–5.6 mmol/L (80–100 mg/dL) in T2DM or 
4.4–7.2 mmol/L (80–130 mg/dL) in T1DM (i.e., treat-to-target approach). Gla-300 and Gla-
100 were administered once-daily in the evening except in EDITION 4 where they were 
given in the morning or evening.  
As expected, all trials confirmed the non-inferiority of Gla-300 and Gla-100 for the change in 
HbA1c from baseline to the end of the 6-month treatment period (Table 4). In general, FPG 
was lowered by a similar extent with Gla-300 and Gla-100, with a statistically significant 
difference in favour of Gla-100 observed in one trial (EDITION 3). Across the trials, changes 
in variability in pre-injection SMPG, and the 8-point SMPG profile were generally similar in 
patients receiving Gla-300 and those receiving Ga-100 [20-22]. In two sub-studies, a flexible 
Gla-300 dosing regimen did not compromise glycaemic control (HbA1c and FPG) or safety 
(hypoglycaemia) versus the fixed dose regimen [46]. In EDITION 4, the risk of 
hypoglycaemia was not affected by the timing of insulin glargine administration (i.e. morning 
or evening injection).  
In all trials, hypoglycaemic events were categorised according to the American Diabetes 
Association definitions [47], as severe (requiring assistance from another individual) or 
confirmed symptomatic or asymptomatic hypoglycaemia (i.e. plasma glucose levels of ≤70 
mg/dL or ≤3.9 mmol/L). Nocturnal hypoglycaemia was defined as confirmed hypoglycaemia 
events occurring in a 6 h time period from 00:00 h to 05:59 h. The percentage of patients 
experiencing ≥1 confirmed (blood glucose ≤70 mg/dL) or severe (American Diabetes 
Association definition) nocturnal hypoglycaemic event was assessed over a range of time 
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periods (week 9 to month 6 [main secondary endpoint in EDITION 1, 2 and 3], baseline to 
week 8, baseline to month 6 and baseline to month 12).  
In general, Gla-300 was associated with a lower risk of nocturnal hypoglycaemia than Gla-
100 in T2DM patients previously on insulin therapy, while the treatment difference in risk of 
nocturnal hypoglycaemia between week 9 and month 6 (the key secondary endpoint in the 
three largest trials) did not reach statistical significance in insulin-naïve patients with T2DM 
[mean reduction of 24% from baseline to 6 months] or in patients with T1DM. Lower rates of 
hypoglycaemia with Gla-300 versus Gla-100 were apparent even during the titration period 
(i.e. baseline to week 8) in most trials. Two trials in insulin-experienced patients (EDITION 1 
and 2) also showed a significantly lower risk of hypoglycaemia during the day. A patient-
level meta-analysis of three trials (EDITION 1, 2 and 3) involving more than 2,400 patients 
with T2DM showed that over the 6-month treatment period, annualised rates of confirmed or 
severe hypoglycaemia were 31% lower with Gla-300 than with Gla-100 during the night 
(2.10 vs. 3.06 events per patient-year; rate ratio 0.69; 95 % CI 0.57–0.84) and 14% lower 
during the day (15.22 vs. 17.73 events per patient-year; rate ratio 0.86; 95 % CI 0.77–0.97) 
[22]. Corresponding rates at 1 year were 2.0 versus 2.4 events per patient-year (rate ratio 
0.82; 95 % CI 0.67–0.99) and 13.7 versus 14.1 events per patient-year (rate ratio 0.97; 95 % 
CI 0.87–1.09) [22]. Overall, these results indicate that the PK and PD properties of Gla-300 
translate into clinically relevant benefits.  
In most trials, weight gain tended to be less with Gla-300 than Gla-100 (~0.26 kg difference 
in T2DM; ~0.56 kg in T1DM) [10], reaching statistical significance at the end of treatment in 
four trials (EDITION 2, 4, JP1 and JP2). The mechanism responsible for this reduced weight 
gain with Gla-300 compared to Gla-100 is not known. Mean total daily insulin dose was also 
consistently higher with Gla-300 than Gla-100 (range 10-18%). The higher dose requirements 
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are consistent with the 17% lower 24-h exposure of Gla-300 compared with Gla-100 at fixed, 
equal doses (0.4 U/kg) [12] and may be attributable to the lower bioavailability of Gla-300 
[10]. 
For a more thorough discussion of the phase III clinical trial data for Gla-300, the reader is 
referred to recent comprehensive reviews [48-50]. 
10. Clinical advantages and disadvantages of Gla-300 
10.1. Advantages 
The different formulation of insulin glargine in Gla-300 results in an improved PK/PD profile 
with a longer duration of action and less variable plasma insulin exposure, compared with 
Gla-100. The 6 randomised trials show a similar efficacy and safety profile, but importantly, 
a lower incidence of hypoglycaemic events with Gla-300 compared with Gla-100, and only a 
slight decrease in body weight gain with Gla-300 despite a 10-18% increase in insulin dose. 
10.2. Disadvantages 
From a clinical perspective, Gla-300 has only been compared with Gla-100 and comparative 
studies with other long- and longer-acting insulins such as insulin detemir and insulin 
degludec would help to determine the place in therapy for this new formulation of insulin 
glargine. Moreover, there are a number of limitations of the completed Phase III EDITION 
trials. These include the open-label design, the relatively short duration (6-12 months) and the 
limited generalisability of the results to other populations with diabetes.  
The 10-18% higher insulin dose required with Gla-300 compared with Gla-100 is an 
important consideration that needs to be balanced against the lower risk of hypoglycaemia, 
minimal decrease in weight gain and a greater degree of flexibility compared with the 
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original insulin glargine formulation. Therefore, cost-effectiveness may be a defining issue in 
the uptake of this new insulin analog. At present, no such data has been reported for Gla-300. 
11. Safety and tolerability 
In all clinical trials conducted to date, Gla-300 was safe and well tolerated, with no 
differences between Gla-300 and Gla-100 with respect to the incidence of adverse events 
(AEs). The most common AEs were hypoglycaemia, allergic reactions, injection site 
reaction, lipodystrophy, pruritus, rash, oedema and weight gain [32]. The sub-studies in 
EDITION 1 and EDITION 2 indicated that the use of adjusted dose intervals did not affect 
the safety profile of Gla-300 [46]. The Gla-300 formulation showed the same good local 
tolerability as the Gla-100 formulation following subcutaneous administration [10].  
Gla-100 and Gla-300 are not bioequivalent and are not directly interchangeable [24]. 
Therefore, switching from Gla-100 to Gla-300 can be done on a unit-to-unit basis, although a 
higher Gla-300 dose (approximately 10-18%) may be needed to achieve target ranges for 
FPG levels. It is recommended that when switching from Gla-300 to Gla-100, the dose 
should initially be reduced (by approximately 20%) to reduce the risk of hypoglycaemia 
before subsequent dose titration [24].  
Blood samples for measurement of insulin antibodies were collected during phase III trials at 
baseline, at weeks 4 and 12, and at month 6 [21]. At baseline, a similar percentage of Gla-300 
and Gla-100 patients were positive for anti-insulin antibodies (AIAs) in T1DM (61.7% and 
53.6%, respectively), as well as T2DM (41.6% and 37.7%) [10]. Throughout the 6-month 
treatment period, the percentage of AIA-positive patients slightly increased in T1DM 
patients, in both the Gla-300 and Gla-100 groups, and remained similar in all T2DM patients. 
Among the AIA-positive patients, the percentage of those with antibodies cross-reacting with 
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human insulin was similar between treatment groups for T1DM and T2DM. No major 
differences over time or between treatment groups were observed for antibody titre. In all of 
the studies, formation of AIAs was similar between Gla-100 and Gla-300 and had no impact 
on the efficacy and safety profiles of either basal insulin.  
12. Regulatory affairs 
Gla-300 was approved for the treatment of diabetes mellitus in adults by the Food and Drug 
Administration (FDA) in February 2015 and by the European Medicines Agency (EMA) in 
April 2015. Gla-300 was licensed in Japan in 2015.  
13. Conclusion 
Gla-300 is a new long-acting insulin glargine formulation that has the same molecular 
structure, mode of protraction (forming precipitates) and metabolism as Gla-100.  
The PK and PD trials described here, show that glycaemic control in T1DM was maintained 
for a longer duration with Gla-300 than Gla-100 (33 h versus 29 h), and insulin exposure was 
more stable and evenly distributed across a 24-h dosing interval with a high level of between-
day reproducibility compared to Gla-100.  
The Phase III EDITION clinical trials indicated that Gla-300 provides a similar level of 
glycaemic control to Gla-100 but with a lower rate of hypoglycaemic events, particularly 
nocturnal episodes. Due to its lower bioavailability, a higher daily dose of Gla-300 may be 
required to achieve a similar glycaemic response. Taken together, the available data suggest 
that Gla-300 represents an attractive alternative to use of Gla-100 for many patients. 
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14. Expert opinion 
The development of new longer-acting basal insulins like Gla-300 represents an important 
advance in insulin therapy for the management of patients with diabetes. Variability in the 
absorption and the modest half-lives of current once-daily basal insulin therapies provide 
challenges in achieving day long (both nocturnal and interprandial) glycaemic control while 
minimising the risk of hypoglycaemia.  
Gla-300 was developed to provide a flatter and more prolonged PK/PD profile compared 
with Gla-100, in order to maintain effective glycaemic control while reducing the risk of 
hypoglycaemia. The studies described here indicate that Gla-300 achieves peak 
concentrations that are lower and delayed, and has a PK exposure that is more stable and 
evenly distributed than Gla-100. The improved PK profile results in an even distribution of 
glucose-lowering effect across a 24-h period, with reduced variability in glucose lowering 
within and between days.  
The improved PK/PD characteristics of Gla-300 are supported by findings from Phase III 
clinical trial programme showing similar glycaemic control to Gla-100 albeit with a 
significantly lower risk of nocturnal hypoglycaemia and similar or significantly less daytime 
hypoglycaemia. This reduced risk of hypoglycaemia with Gla-300 is a potentially important 
finding, given that clinical concern relating to hypoglycaemia is often a barrier to effective 
dose adjustment and attainment of target glycaemic control. The lower risk of hypoglycaemia 
with Gla-300 observed during the titration period may also allow for a smoother, safer and 
more reliable insulin titration [20-22], leading to improved confidence in increasing the dose 
for both physicians and patients with diabetes [20].  
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The need for a 10-18% higher insulin requirement with Gla-300 versus Gla-100 is related to 
its reduced bioavailability following subcutaneous administration. The economic 
consequences of this higher dose requirement will need to be balanced against the reduced 
propensity for hypoglycaemia. Moreover, despite the higher doses of Gla-300, weight gain 
did not increase significantly, indeed a modest, but statistically significant reduction in body 
weight gain was observed in several of the Phase III clinical trials. The difference in body 
weight (~0.25 kg) between the two two insulin formulations at 6 months is relatively minor. 
Gla-300 appears to be associated with greater flexibility in time-of-day dosing, which may 
make it easier to achieve optimal insulin titration in clinical practice. This is likely to be of 
greatest benefit to those patients who find it difficult to adhere to the precise timing of 
injections required. Further studies will be required to verify the findings observed in these 
short-term studies, and results from additional studies in the elderly and children are expected 
over the next few years. 
Besides Gla-300, insulin degludec has been approved in many countries. As both of these 
insulin therapies show a similar long-action profile of more than 36 h, each has the potential 
to become a central insulin therapy for patients with T1DM and T2DM. The lack of 
comparative trial between these two new therapies means that indirect comparisons will need 
to be made in the future. In this respect, a recent network meta-analysis compared Gla-300 
with other basal insulin therapies used for patients with T2DM [51], and suggested that Gla-
300 is associated with glycaemic control comparable to available basal insulin comparators 
(degludec and detemir), has a similar risk of symptomatic hypoglycaemia versus other 
therapies (degludec, detemir and NPH), and a significantly lower risk of nocturnal 
hypoglycaemia compared with NPH and premixed insulin.  
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In summary, the available evidence suggests that Gla-300 represents an important advance in 
insulin treatment for patients with diabetes.  
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15. Box 1. Drug summary 
 
Drug name Insulin glargine injection 300 units/mL (Toujeo) 
Phase Approved by FDA in February 2015 and by EMA in April 2015 
Indication Treatment of diabetes mellitus in adults 
Pharmacology description Long-acting recombinant insulin analog 
Route of administration Subcutaneous injection 
Chemical structure  
 
Depot: Gla-300 forms a compact subcutaneous depot with a smaller surface area to produce 
more gradual and prolonged release compared with Gla-100  
 
Pivotal trial (s) EDITION 1 [36], EDITION 2 [20], EDITION 3 [37], EDITION 4 [21], 
EDITION JP1 [38] and EDITION JP2 [39] 
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Table 1 Summary of PK/PD phase I and II trials of Gla-300 
Authors, year  Population  N Design Main objectives 
Euglycaemic clamp 
(Device, duration) 
Gla-300 dose 
(U/kg/day) 
Gla-100 dose 
(U/kg/day) 
0.4 0.6 0.9 0.4 
Single dose, Phase I          
PKD10086 [10] Healthy volunteers 24 R, CO Bioequivalence  (Not known)     
Single dose, Phase I         
Shiramoto 2015 [11] T1DM (Japanese) 18 R, DB, CO PK/PD  (STG-22, 36 h)     
Shiramoto 2015 [11] T1DM (European) 24 R, DB, CO PK/PD  (Biostator, 36 h)     
Steady state, Phase I          
Becker 2015 [12] T1DM (European) 30 R, DB, CO PK/PD  (Biostator, 36 h)     
Becker 2015 [13] T1DM (European) 50 R, DB, CO Bioequivalence  (Biostator, 24 h)     
Jinnouchi 2015 [14] T1DM (Japanese) 18 R, OL, CO PK/PD, CGM x (CGM)     
Steady state, Phase II          
Bergenstal 2014 [15] T1DM 59 R, OL, CO Glucose control x (CGM)     
CGM, continuous glucose monitoring; CO, crossover; DB, double blind; OL, open label; PK, pharmacokinetic; PD, pharmacodynamic; R, 
randomised,  
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Table 2 PK and PD characteristics after a single dose in (A) European and (B) Japanese patients with T1DM [11] 
 Gla-100 dose (U/kg)  Gla-300 dose (U/kg) 
 
0.4  0.4 0.6 0.9 
(A) European (n=15-22)      
INS-Cmax, µU/mL 15.3 ± 6.0  8.9 ± 2.9 9.3 ± 2.8 13.0 ± 6.2 
INS-AUC0–36, µU·h/mL 318 ± 109  195 ± 89 206 ± 105 327 ± 139 
T50%-INS-AUC0-36, h 13 (12–15)  15 (12–19) 17 (14–20) 19 (17–19) 
INS-Tmax, h 12 (8–12)  12 (8–14) 12 (12–18) 16 (12–20) 
GIR-AUC0–36, mg/kg 1725 ± 920   631 ± 590 1118 ± 1018 1845 ± 765 
GIRmax, mg/kg/min* 2.2 ± 0.9   1.6 ± 1.1 1.5 ± 0.9 2.2 ± 0.7 
T50%-GIR-AUC0–36, h 12 (11–13)  17 (12–24) 17 (14–23) 19 (18–22) 
(B) Japanese (n=15-18)      
INS-Cmax, µU/mL 17.3 ± 4.8  10.9 ± 3.4 13.8 ± 7.1 - 
INS-AUC0–36, µU·h/mL 370 ± 101  251 ± 92 326 ± 156 - 
T50%-INS-AUC0–36, h 14 (12–15)  17 (13–19) 18 (16–18) - 
INS-Tmax, h 8 (2–12)  16 (12–16) 14 (8–16) - 
GIR-AUC0–36, mg/kg 1859 ± 1085   990 ± 1233 1591 ± 1719  
GIRmax, mg/kg/min* 2.2 ± 0.8   1.2 ± 1.0 1.8 ± 1.3  
T50%-GIR-AUC0–36, h 13 (10–15)   17 (14–21)§ 18 (15–21)  
All data are mean ± SD or median (interquartile range) for T50%-INS-AUC0-36, INS-Tmax, T50%-GIR-AUC0–36 and T50%-GIR-AUC0–24. The values 
in bold indicate a statistically significant difference between Gla-300 and Gla-100 0.4 U/kg (p<0.05 or < 0.1 for INS-Tmax). Gla-100, insulin 
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glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; INS, insulin glargine concentration; INS-Cmax, maximum serum insulin concentration; 
INS-AUC0–36, area under the concentration versus time curve from time 0 to 36 h; INS-Tmax, time to INS-Cmax; T50%-INS-AUC0–36, time to 50% 
of INS-AUC0–36  
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Table 3 PK and PD parameters at steady state after multiple doses of Gla-300 and Gla-100 0.4 U/kg [12] 
 
Gla-100 0.4 U/kg (n=17-18) Gla-300 0.4 U/kg (n=16-17) 
INS-Cmax, µU/mL 23.4 ± 8.4 18.1 ± 6.5 
INS-AUC0–36, µU·h/mL 438 ± 167 418 ± 186 
T50%-INS-AUC0–36, h 10.9 (10–12) 14.0 (12–15) 
INS-t1/2, h 13.5 ± 6.9 19.0 ± 6.4 
ΔINS, µU/mL* 15 (11–18) 9 (5–10) 
Swing¶ 1.8 (1.3–2.3) 0.8 (0.6–1.0) 
GIR-AUC0–36, mg/kg 2,614 (1,182) 2,432 (1,379) 
GIRmax, mg/kg/min 3.2 (2.6–3.8) 2.5 (1.8–3.4) 
T50%-GIR-AUC0–36, h 11.0 (9–12) 14.4 (11–16) 
All data are mean ± SD or median (interquartile range) for T50%-INS-AUC0-36, ΔINS, Swing, GIRmax, T50%-GIR-AUC0–36 
*INS-Cmax− INS-C24.¶ (INS-Cmax − INS-C24)/INS-C24. 
INS-Cmax, maximum serum insulin concentration; INS-t1/2; terminal half-life of serum insulin concentration; INS-AUC0–36; area under the 
concentration versus time curve from time 0 to 36 hours; GIRmax, maximum smoothed body-weight–standardised GIR (LOESS factor of 0.06). 
The values in bold indicate a statistically significant difference between Gla-300 and Gla-100 0.4 U/kg.  
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Table 4 Summary of findings from randomised, open-label 6-month Phase III clinical trials comparing Gla-300 with Gla-100 
Study population Study name No. patients 
HbA1c reduction 
with Gla-300 vs. 
Gla-100, ETD (%) 
FPG reduction 
with Gla-300 vs. 
Gla-100, ETD 
(mmol/L) 
Hypoglycaemia events (% 
reduction)
a
 Mean daily dose 
Gla-300 vs.  
Gla-100 At any time 
of day
b
 (
c
) 
Nocturnal
b
 (
c
) 
Type 2 diabetes: Insulin-experienced patients      
On BB insulin + OADs EDITION 1 807 [36] -0.00%; non-inferior 0.09 ↓7% (↓4%) ↓18% (↓21%)  ↑10% 
On basal insulin + OADs EDITION 2 811 [20] -0.01%; non-inferior 0.19 ↓10% (↓9%) ↓29% (↓23%)  ↑10% 
On basal insulin + OADs EDITION JP2 241 [39] 0.04%; non-inferior 0.04 ↓14% (↓16%) ↓38% (↓42%) ↑17% 
Type 2 diabetes: Insulin-naive patients      
On OADs EDITION 3 878 [37] 0.04%; non-inferior -0.39 ↓12% (↓14%) ↓24% (↓11%) ↑17% 
Type 1 diabetes        
On BB insulin EDITION 4 549 [21] 0.04%; non-inferior 0.19 0% (↓2%) ↓2% (↑6%) ↑18% 
On BB insulin EDITION JP1 243 [38] 0.13%; non-inferior 0.4 ↓1% (↑1%) ↓15% (↓16%) ↑17% 
The values in bold indicate a statistically significant difference between Gla-300 and Gla-100 (p<0.05) 
BB, basal-bolus; ETD, estimated treatment difference; OADs, oral antidiabetic therapy; RAI, rapid-acting insulin 
a
Patients experiencing ≥1 confirmed (blood glucose ≤70 mg/dL [≤3.9mmol/L]) or severe hypoglycaemic event  
b
Between baseline and month 6.  
c
Between week 9 and month 6 (key secondary endpoint in EDITION 1, 2 and 3). The time period was chosen to avoid any possibility of 
temporary alteration of the risk of hypoglycaemia following a switch from a known therapy (in most cases Gla-100) to an unfamiliar new 
insulin. 
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Figure 1: Mechanism of slower release from subcutaneous tissue of Gla-300 compared with 
Gla-100 (A) Curve illustrating how the smaller injection volume of Gla-300 translates to a 
smaller surface area in depot injection (B) Curve illustrating the concentration dependent 
release capacity of Gla-300 which is released more slowly than Gla-100 as the release rate is 
proportional to the surface area of the depot. Dp/dt indicates the glargine dispersal rate over 
time 
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Figure 2 Median insulin (INS) concentration profiles (LLOQ = 5.02 μU/mL) (A), and smoothed (LOESS factor 0.15) 36-h body weight 
standardised glucose infusion rate profiles (B), with Gla-300 and Gla-100 following single dose administration in Japanese and European 
patients with T1DM. Reprinted from [11] with permission of John Wiley and Sons.  
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Figure 3 Mean insulin concentration (A), smoothed body weight standardised glucose 
infusion rate (B), and smoothed blood glucose measures (C) with Gla-300 and Gla-100 0.4 
U/kg at steady state following 8 days of once-daily administration in subjects with T1DM 
(n=30). Thirty-six-hour mean blood glucose profiles during this clamp study. Reproduced 
from [12] with permission from American Diabetes Association. 
 
 
 
BG, blood glucose; Gla-100, insulin glargine 100 units/mL; Gla-300, insulin glargine 300 
units/mL; LLOQ, lower limit of quantification.  
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Figure 4 Pharmacokinetic and pharmacodynamic profiles for Gla-300 at steady state, by 
treatment period [13]. Profiles of (A) mean (standard deviation) serum insulin concentration 
(INS), lower limit of quantification (LLOQ) = 5.02 µU/mL. Two individual far outside values 
excluded (one in period 1, h 14 and one in period 2, h 8) ; and (B) Mean smoothed (LOESS 
factor 0.06) body-weight-standardised glucose infusion rate (GIR). in a crossover 
euglycaemic study of Gla-300 0.4 U/kg in 50 patients with T1DM. The percentage 
contribution of each 6 hour interval to the total AUCGIR is shown in the Figure. Reprinted 
from [13] with permission of John Wiley and Sons.  
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Figure 5 A) Median trough levels of M1 with an exponential regression of the data. The two 
Gla-100 reference groups are combined as a weighted average of the medians. B) M1 profiles 
at steady state. Reprinted from [25] with permission of John Wiley and Sons.  
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Figure 6 Mean 24-h glucose profiles with Gla-300 vs Gla-100 when administered in the morning or evening during the last 2 weeks of each 
treatment period (continuous glucose monitoring population; pooled data period A + B) [15] 
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